NO20030658L - Method for Modeling Multiple Lineage Kinase Proteins and Investigation of Compounds Modulating Multiple Lineage Kinase Proteins - Google Patents
Method for Modeling Multiple Lineage Kinase Proteins and Investigation of Compounds Modulating Multiple Lineage Kinase ProteinsInfo
- Publication number
- NO20030658L NO20030658L NO20030658A NO20030658A NO20030658L NO 20030658 L NO20030658 L NO 20030658L NO 20030658 A NO20030658 A NO 20030658A NO 20030658 A NO20030658 A NO 20030658A NO 20030658 L NO20030658 L NO 20030658L
- Authority
- NO
- Norway
- Prior art keywords
- kinase proteins
- lineage kinase
- multiple lineage
- investigation
- modeling
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63705400A | 2000-08-11 | 2000-08-11 | |
| PCT/US2001/024822 WO2002014536A2 (en) | 2000-08-11 | 2001-08-08 | Odulating multiple lineage kinase proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20030658D0 NO20030658D0 (en) | 2003-02-10 |
| NO20030658L true NO20030658L (en) | 2003-04-09 |
Family
ID=24554347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20030658A NO20030658L (en) | 2000-08-11 | 2003-02-10 | Method for Modeling Multiple Lineage Kinase Proteins and Investigation of Compounds Modulating Multiple Lineage Kinase Proteins |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1309721A2 (en) |
| JP (1) | JP2005503102A (en) |
| CN (1) | CN1458979A (en) |
| AU (2) | AU2001283179B2 (en) |
| BG (1) | BG107623A (en) |
| BR (1) | BR0113266A (en) |
| CA (1) | CA2419985A1 (en) |
| CZ (1) | CZ2003680A3 (en) |
| HR (1) | HRP20030162A2 (en) |
| HU (1) | HUP0501110A3 (en) |
| IL (1) | IL154311A0 (en) |
| IS (1) | IS6711A (en) |
| MX (1) | MXPA03001218A (en) |
| NO (1) | NO20030658L (en) |
| NZ (1) | NZ524034A (en) |
| PL (1) | PL366248A1 (en) |
| SK (1) | SK2692003A3 (en) |
| WO (1) | WO2002014536A2 (en) |
| ZA (1) | ZA200301109B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6811992B1 (en) | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
| AU2004257748B2 (en) * | 2003-07-14 | 2008-10-30 | Decode Genetics Ehf. | Method of diagnosis and treatment for asthma based on haplotype association |
| US20060014165A1 (en) * | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
| US20060058250A1 (en) * | 2004-09-10 | 2006-03-16 | Cephalon, Inc. | Methods of treating proliferative skin diseases using carbazole derivatives |
| WO2014172616A2 (en) * | 2013-04-18 | 2014-10-23 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| KR101892457B1 (en) * | 2016-11-25 | 2018-08-31 | 주식회사 샤인바이오 | Composition for promoting and protecting the differentiation of neural stem cells and a method for inducing neural regeneration using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756494A (en) * | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
| US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US6811992B1 (en) * | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
| CN1879617A (en) * | 1998-08-26 | 2006-12-20 | 赛福伦公司 | Modulating multiple lineage kinase proteins |
| US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
-
2001
- 2001-08-08 JP JP2002519661A patent/JP2005503102A/en active Pending
- 2001-08-08 IL IL15431101A patent/IL154311A0/en unknown
- 2001-08-08 MX MXPA03001218A patent/MXPA03001218A/en not_active Application Discontinuation
- 2001-08-08 CZ CZ2003680A patent/CZ2003680A3/en unknown
- 2001-08-08 HU HU0501110A patent/HUP0501110A3/en unknown
- 2001-08-08 NZ NZ524034A patent/NZ524034A/en unknown
- 2001-08-08 HR HR20030162A patent/HRP20030162A2/en not_active Application Discontinuation
- 2001-08-08 BR BR0113266-0A patent/BR0113266A/en not_active IP Right Cessation
- 2001-08-08 EP EP01961958A patent/EP1309721A2/en not_active Withdrawn
- 2001-08-08 AU AU2001283179A patent/AU2001283179B2/en not_active Ceased
- 2001-08-08 WO PCT/US2001/024822 patent/WO2002014536A2/en not_active Ceased
- 2001-08-08 AU AU8317901A patent/AU8317901A/en active Pending
- 2001-08-08 CA CA002419985A patent/CA2419985A1/en not_active Abandoned
- 2001-08-08 CN CN01814001A patent/CN1458979A/en active Pending
- 2001-08-08 PL PL01366248A patent/PL366248A1/en not_active Application Discontinuation
- 2001-08-08 SK SK269-2003A patent/SK2692003A3/en not_active Application Discontinuation
-
2003
- 2003-02-10 ZA ZA200301109A patent/ZA200301109B/en unknown
- 2003-02-10 NO NO20030658A patent/NO20030658L/en not_active Application Discontinuation
- 2003-02-10 IS IS6711A patent/IS6711A/en unknown
- 2003-03-10 BG BG107623A patent/BG107623A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL154311A0 (en) | 2003-09-17 |
| CN1458979A (en) | 2003-11-26 |
| BR0113266A (en) | 2005-01-04 |
| HUP0501110A2 (en) | 2006-03-28 |
| JP2005503102A (en) | 2005-02-03 |
| CA2419985A1 (en) | 2002-02-21 |
| CZ2003680A3 (en) | 2003-11-12 |
| PL366248A1 (en) | 2005-01-24 |
| SK2692003A3 (en) | 2003-08-05 |
| WO2002014536A2 (en) | 2002-02-21 |
| MXPA03001218A (en) | 2003-05-27 |
| WO2002014536A3 (en) | 2003-01-30 |
| NZ524034A (en) | 2006-11-30 |
| IS6711A (en) | 2003-02-10 |
| HRP20030162A2 (en) | 2005-12-31 |
| NO20030658D0 (en) | 2003-02-10 |
| EP1309721A2 (en) | 2003-05-14 |
| BG107623A (en) | 2003-11-28 |
| ZA200301109B (en) | 2004-07-20 |
| AU8317901A (en) | 2002-02-25 |
| WO2002014536A9 (en) | 2003-12-18 |
| HUP0501110A3 (en) | 2006-06-28 |
| AU2001283179B2 (en) | 2006-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2022009I2 (en) | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF MULTIPLIARY DISEASES | |
| NO973479L (en) | Substituted heterocyclic compounds, method of preparation and pharmaceutical compositions containing the same | |
| CY2012029I1 (en) | NEW FORM OF S-OMEPRAZOLE | |
| NO974572D0 (en) | Cyclodextrin Compounds, Methods of Preparation and Use | |
| DE69627179D1 (en) | SUBSTITUTED 2-ANILINO-PYRIMIDINES USED AS PROTEIN KINASE INHIBITORS | |
| ATE172199T1 (en) | PROTEIN KINASE C INHIBITOR | |
| DE60121953D1 (en) | METHOD OF MANUFACTURING MEDICINE PREPARATIONS | |
| FI945706A7 (en) | Protein kinase C inhibitors | |
| NO20020635L (en) | Inhibitors of protein polymerization and the methods used | |
| EP1087770A4 (en) | INHIBITORS OF PRENYL PROTEIN TRANSFERASE | |
| NO20003067D0 (en) | Antipicornavirus compounds and methods for their use and preparation | |
| NO995695D0 (en) | Substituted pyrazoles as p38 kinase inhibitors | |
| DE60210816D1 (en) | PROCESS FOR THE PREPARATION OF 1- (CARBOXYMETHYL) AND 1 (AMINOCARBONYL) -PYRIMIDIN-4-ON DERIVATIVES | |
| NO20003070L (en) | Substituted thiazolidine derivative, method of preparation and use thereof | |
| NO20012963L (en) | Process for the preparation of 3-alkanoylindoles and 3-alkylindoles | |
| EP1451587A4 (en) | ANTIGEN PANELS AND METHODS OF USE THEREOF | |
| FI955661A7 (en) | Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors | |
| EE04154B1 (en) | Method of preparation of omeprazole | |
| NO20033506L (en) | Parasiticidal preparations and methods of use | |
| NO985248L (en) | Indolylpyrrolidene methylpyrrole derivatives and process for their preparation | |
| NO20025069L (en) | New stable crystal of thiazolidinedione derivative and process for preparing the same | |
| NO20030658L (en) | Method for Modeling Multiple Lineage Kinase Proteins and Investigation of Compounds Modulating Multiple Lineage Kinase Proteins | |
| NO994209D0 (en) | Process for the preparation of 2 - [[(2-pyridinyl) methyl] sulfinyl] -1H-benzimidazoles and novel compounds for use in this formula | |
| DK0906268T3 (en) | Alkoxyamino-substituted fluorenones and their use as protein kinase C inhibitors | |
| IT1309715B1 (en) | METHOD AND EQUIPMENT FOR THE CREATION OF MUSICAL ACCOMPANIMENTS BY METAMORPHOSIS OF STYLES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |